Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VDJ010
- Development stage
- Unknown
- Lead developer
- Beijing VDJBio
- Administration
- Subcutaneous
01
Overview
VDJ010 is a long-acting biologic regulatory T cell (Treg) activator developed by Beijing VDJBio (Beijing Weidejie Biotechnology Co., Ltd.). It is designed to selectively activate and expand the Treg population, which plays a critical role in maintaining immune tolerance and suppressing excessive immune responses. By promoting immune homeostasis, VDJ010 aims to treat various autoimmune and inflammatory conditions, including Systemic Lupus Erythematosus, Sjögren's syndrome, Inflammatory Bowel Disease (specifically ulcerative colitis), and Amyotrophic Lateral Sclerosis. The drug is currently in Phase 1 clinical development and is administered via subcutaneous injection.
Beyond the preview
Go deeper on VDJ010.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VDJ010.